|
1
|
World Health Organization: Cancer Fact
Sheets: Stomach Cancer. WHO, Geneva, 2020.
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Song Y, Liu X, Cheng W, Li H and Zhang D:
The global, regional and national burden of stomach cancer and its
attributable risk factors from 1990 to 2019. Sci Rep.
12(11542)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
GBD 2017 Stomach Cancer Collaborators. The
global, regional, and national burden of stomach cancer in 195
countries, 1990-2017: A systematic analysis for the global burden
of disease study 2017. Lancet Gastroenterol Hepatol. 5:42–54.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Maconi G, Manes G and Porro GB: Role of
symptoms in diagnosis and outcome of gastric cancer. World J
Gastroenterol. 14:1149–1155. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sitarz R, Skierucha M, Mielko J, Offerhaus
GJA, Maciejewski R and Polkowski WP: Gastric cancer: Epidemiology,
prevention, classification, and treatment. Cancer Manag Res.
10:239–248. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Boniface MM, Wani SB, Schefter TE, Koo PJ,
Meguid C, Leong S, Kaplan JB, Wingrove LJ and McCarter MD:
Multidisciplinary management for esophageal and gastric cancer.
Cancer Manag Res. 8:39–44. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Guan WL, He Y and Xu RH: Gastric cancer
treatment: Recent progress and future perspectives. J Hematol
Oncol. 16(57)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Song Z, Wu Y, Yang J, Yang D and Fang X:
Progress in the treatment of advanced gastric cancer. Tumour Biol.
39(1010428317714626)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shah MA and Ajani JA: Gastric cancer-an
enigmatic and heterogeneous disease. JAMA. 303:1753–1754.
2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ajani JA, Bentrem DJ, Besh S, D'Amico TA,
Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, et
al: Gastric cancer, version 2.2013: Featured updates to the NCCN
guidelines. J Natl Compr Cancer Netw. 11:531–546. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu J, Lin PC and Zhou BP: Inflammation
fuels tumor progress and metastasis. Curr Pharm Des. 21:3032–3040.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J,
Xin Y, Wang Y, Yang C and Cheng Y: Systemic immune-inflammation
index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio
can predict clinical outcomes in patients with metastatic
non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal.
33(e22964)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Wang S, Yang X, Yu Z, Du P, Cao Y, Ji Y,
Ma J and Yang Y: The values of systemic immune-inflammation index
and neutrophil-lymphocyte ratio in predicting testicular germ cell
tumors: A retrospective clinical study. Front Oncol.
12(893877)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xia LJ, Li W, Zhai JC, Yan CW, Chen JB and
Yang H: Significance of neutrophil-to-lymphocyte ratio,
platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and
prognostic nutritional index for predicting clinical outcomes in
T1-2 rectal cancer. BMC Cancer. 20(208)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhu S, Cheng Z, Hu Y, Chen Z, Zhang J, Ke
C, Yang Q, Lin F, Chen Y and Wang J: Prognostic value of the
systemic immune-inflammation index and prognostic nutritional index
in patients with medulloblastoma undergoing surgical resection.
Front Nutr. 8(754958)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang Y, Gao Y, Wu Y and Lin H: Prognostic
value of systemic immune-inflammation index in patients with
urologic cancers: A meta-analysis. Cancer Cell Int.
20(499)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang R, Chang Q, Meng X, Gao N and Wang W:
Prognostic value of systemic immune-inflammation index in cancer: A
meta-analysis. J Cancer. 9:3295–3302. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li X, Zhang S, Lu J, Li C and Li N: The
prognostic value of systemic immune-inflammation index in surgical
esophageal cancer patients: An updated meta-analysis. Front Surg.
9(922595)2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hong X, Cui B, Wang M, Yang Z, Wang L and
Xu Q: Systemic immune-inflammation index, based on platelet counts
and neutrophil-lymphocyte ratio, is useful for predicting prognosis
in small cell lung cancer. Tohoku J Exp Med. 236:297–304.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Qiu Y, Zhang Z and Chen Y: Prognostic
value of pretreatment systemic immune-inflammation index in gastric
cancer: A meta-analysis. Front Oncol. 11(537140)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fu S, Yan J, Tan Y and Liu D: Prognostic
value of systemic immune-inflammatory index in survival outcome in
gastric cancer: A meta-analysis. J Gastrointest Oncol. 12:344–354.
2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wells G, Shea B, O'Connell D, Robertson J,
Peterson J, Losos M and Tugwell P: The newcastle-ottawa scale (NOS)
for assessing the quality of nonrandomized studies in
meta-analysis. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Accessed on April 29, 2023.
|
|
25
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Egger M, Smith GD, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gu L, Wang M, Cui X, Mo J, Yuan L, Mao F,
Zhang K, Ng DM, Chen P and Wang D: Clinical significance of
peripheral blood-derived inflammation markers in advanced gastric
cancer after radical resection. BMC Surg. 20(219)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Demircan NC, Atcı MM, Demir M, Işık S and
Akagündüz B: Dynamic changes in systemic immune-inflammation index
predict pathological tumor response and overall survival in
patients with gastric or gastroesophageal junction cancer receiving
neoadjuvant chemotherapy. Asia Pac J Clin Oncol. 19:104–112.
2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Inoue H, Kosuga T, Kubota T, Konishi H,
Shiozaki A, Okamoto K, Fujiwara H and Otsuji E: Significance of a
preoperative systemic immune-inflammation index as a predictor of
postoperative survival outcomes in gastric cancer. World J Surg
Oncol. 19(173)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wei C, Li C, Chen X, Chen G, Nie R, Zhao
C, Zhou Z and Chen Y: Development and verification of a nomogram
for predicting the prognosis of resectable gastric cancer with
outlet obstruction. BMC Cancer. 22(1154)2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhaojun X, Xiaobin C, Juan A, Jiaqi Y,
Shuyun J, Tao L, Baojia C, Cheng W and Xiaoming M: Correlation
analysis between preoperative systemic immune inflammation index
and prognosis of patients after radical gastric cancer surgery:
Based on propensity score matching method. World J Surg Oncol.
20(1)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang SB, Chen JY, Xu C, Cao WG, Cai R, Cao
L and Cai G: Evaluation of systemic inflammatory and nutritional
indexes in locally advanced gastric cancer treated with adjuvant
chemoradiotherapy after D2 dissection. Front Oncol.
12(1040495)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Qu Z, Wang Q, Wang H, Jiao Y, Li M, Wei W,
Lei Y, Zhao Z, Zhang T, Zhang Y and Gu K: The effect of
inflammatory markers on the survival of advanced gastric cancer
patients who underwent anti-programmed death 1 therapy. Front
Oncol. 12(783197)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wan M, Ding Y, Mao C, Ma X, Li N, Xiao C,
Qian J, Jiang H, Zheng Y, Wu L, et al: Association of inflammatory
markers with survival in patients with advanced gastric cancer
treated with immune checkpoint inhibitors combined with
chemotherapy as first line treatment. Front Oncol.
12(1029960)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Yekedüz E, Dogan İ, Kaya D, MÖzgür İ,
Utkan G, Vatansever S, Demirci S, Akbulut H and Ürün Y: Systemic
immune-inflammation index as a prognostic marker of late recurrence
in operable gastric cancer: A dual-center study. J Gastrointest
Cancer. 53:870–879. 2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Liu YY, Ruan GT, Ge YZ, Li QQ, Zhang Q,
Zhang X, Tang M, Song MM, Zhang XW, Li XR, et al: Systemic
inflammation with sarcopenia predicts survival in patients with
gastric cancer. J Cancer Res Clin Oncol. 149:1249–1259.
2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Uzunoglu H and Kaya S: Does systemic
immune inflammation index have predictive value in gastric cancer
prognosis? North Clin Istanb. 10:24–32. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang H, Yin X, Ma K, Wang Y, Fang T, Zhang
Y and Xue Y: Nomogram based on preoperative fibrinogen and systemic
immune-inflammation index predicting recurrence and prognosis of
patients with borrmann type III advanced gastric cancer. J Inflamm
Res. 16:1059–1075. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
He K, Si L, Pan X, Sun L, Wang Y, Lu J and
Wang X: Preoperative systemic immune-inflammation index (SII) as a
superior predictor of long-term survival outcome in patients with
stage I-II gastric cancer after radical surgery. Front Oncol.
12(829689)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Chen Y, Zhang C, Peng Z, Qi C, Gong J,
Zhang X, Li J and Shen L: Association of lymphocyte-to-monocyte
ratio with survival in advanced gastric cancer patients treated
with immune checkpoint inhibitor. Front Oncol.
11(589022)2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shi H, Wang H, Pan J, Liu Z and Li Z:
Comparing prognostic value of preoperative platelet indexes in
patients with resectable gastric cancer. Sci Rep.
12(6480)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wang PX, Wang HJ, Liu JH, Qiu GL, Lu J,
Fan L, Liao XH and Che XM: A nomogram combining plasma fibrinogen
and systemic immune-inflammation index predicts survival in
patients with resectable gastric cancer. Sci Rep.
11(10301)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Huang L, Liu S, Lei Y, Wang K, Xu M, Chen
Y, Liu B, Chen Y, Fu Q, Zhang P, et al: Systemic
immune-inflammation index, thymidine phosphorylase and survival of
localized gastric cancer patients after curative resection.
Oncotarget. 7:44185–44193. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chen L, Yan Y, Zhu L, Cong X, Li S, Song
S, Song H and Xue Y: Systemic immune-inflammation index as a useful
prognostic indicator predicts survival in patients with advanced
gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag
Res. 9:849–867. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang K, Diao F, Ye Z, Zhang X, Zhai E, Ren
H, Li T, Wu H, He Y, Cai S and Chen J: Prognostic value of systemic
immune-inflammation index in patients with gastric cancer. Chin J
Cancer. 36(75)2017.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Guo J, Chen S, Chen Y, Li S and Xu D:
Combination of CRP and NLR: A better predictor of postoperative
survival in patients with gastric cancer. Cancer Manag Res.
10:315–321. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Shi H, Jiang Y, Cao H, Zhu H, Chen B and
Ji W: Nomogram based on systemic immune-inflammation index to
predict overall survival in gastric cancer patients. Dis Markers.
2018(1787424)2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wang Q and Zhu D: The prognostic value of
systemic immune-inflammation index (SII) in patients after radical
operation for carcinoma of stomach in gastric cancer. J
Gastrointest Oncol. 10:965–978. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Yılmaz A, Mirili C, Tekin SB and Bilici M:
The ratio of hemoglobin to red cell distribution width predicts
survival in patients with gastric cancer treated by neoadjuvant
FLOT: A retrospective study. Ir J Med Sci. 189:91–102.
2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hirahara N, Tajima Y, Matsubara T, Fujii
Y, Kaji S, Kawabata Y, Hyakudomi R, Yamamoto T, Uchida Y and
Taniura T: Systemic immune-inflammation index predicts overall
survival in patients with gastric cancer: A propensity
score-matched analysis. J Gastrointest Surg. 25:1124–1133.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lin JX, Wang ZK, Huang YQ, Xie JW, Wang
JB, Lu J, Chen QY, Lin M, Tu RH, Huang ZN, et al: Dynamic changes
in pre- and postoperative levels of inflammatory markers and their
effects on the prognosis of patients with gastric cancer. J
Gastrointest Surg. 25:387–396. 2021.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhou W, Wu J, Wang Q, Zhang H, Jiang J and
Wu C: Evaluate the correlation between preoperative systemic
immune-inflammation index and prognosis of patients after curative
resection for cardia gastric cancer. Chin Med Biotechnol.
11:510–514. 2016.(In Chinese).
|
|
53
|
Liu X, Sun X, Liu J, Kong P, Chen S, Zhan
Y and Xu D: Preoperative C-reactive protein/albumin ratio predicts
prognosis of patients after curative resection for gastric cancer.
Transl Oncol. 8:339–345. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Fang T, Yin X, Wang Y, Zhang L, Zhang X,
Zhao X, Wang Y and Xue Y: Proposed models for prediction of
mortality in stage-I and stage-II gastric cancer and 5 years after
radical gastrectomy. J Oncol. 2022(4510000)2022.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Yin X, Fang T, Wang Y, Li C, Wang Y, Zhang
D and Xue Y: Efficacy of postoperative FOLFOX versus XELOX
chemotherapy for gastric cancer and prognostic value of
platelet-lymphocyte ratio in patients receiving XELOX. Front Oncol.
10(584772)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Zhu Z, Cong X, Li R, Yin X, Li C and Xue
Y: Preoperative systemic immune-inflammation index (SII) for
predicting the survival of patients with stage I-III gastric cancer
with a signet-ring cell (SRC) component. BioMed Res Int.
2020(e5038217)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhong JH, Huang DH and Chen ZY: Prognostic
role of systemic immune-inflammation index in solid tumors: A
systematic review and meta-analysis. Oncotarget. 8:75381–75388.
2017.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wang Y, Li Y, Chen P, Xu W, Wu Y and Che
G: Prognostic value of the pretreatment systemic
immune-inflammation index (SII) in patients with non-small cell
lung cancer: A meta-analysis. Ann Transl Med. 7(433)2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Wang B, Huang Y and Lin T: Prognostic
impact of elevated pre-treatment systemic immune-inflammation index
(SII) in hepatocellular carcinoma: A meta-analysis. Medicine
(Baltimore). 99(e18571)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Santoiemma PP and Powell DJ Jr: Tumor
infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther.
16:807–820. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Whiteside TL: Tumor-infiltrating
lymphocytes and their role in solid tumor progression. Exp Suppl.
113:89–106. 2022.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Zhao J, Huang W, Wu Y, Luo Y, Wu B, Cheng
J, Chen J, Liu D and Li C: Prognostic role of pretreatment blood
lymphocyte count in patients with solid tumors: A systematic review
and meta-analysis. Cancer Cell Int. 20(15)2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ménétrier-Caux C, Ray-Coquard I, Blay JY
and Caux C: Lymphopenia in cancer patients and its effects on
response to immunotherapy: An opportunity for combination with
Cytokines? J Immunother Cancer. 7(85)2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Koizumi K, Hojo S, Akashi T, Yasumoto K
and Saiki I: Chemokine receptors in cancer metastasis and cancer
cell-derived chemokines in host immune response. Cancer Sci.
98:1652–1658. 2007.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Masucci MT, Minopoli M and Carriero MV:
Tumor associated neutrophils. Their role in tumorigenesis,
metastasis, prognosis and therapy. Front Oncol.
9(1146)2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Xiong S, Dong L and Cheng L: Neutrophils
in cancer carcinogenesis and metastasis. J Hematol Oncol.
14(173)2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Uribe-Querol E and Rosales C: Neutrophils
in cancer: Two sides of the same coin. J Immunol Res.
2015(983698)2015.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Palacios-Acedo AL, Mège D, Crescence L,
Dignat-George F, Dubois C and Panicot-Dubois L: Platelets,
thrombo-inflammation, and cancer: Collaborating with the enemy.
Front Immunol. 10(1805)2019.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011.PubMed/NCBI View Article : Google Scholar
|
